Clinical Trial

Ketamine Infusions for Comorbid PTSD and MDD in Veterans

Study Description

Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans

Co-occurring post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) is the most common response to trauma; it is associated with poor clinical outcomes and substantial human disability. Veterans with both PTSD and MDD (PTSD+MDD) have been shown to be at much greater suicidal risk than individuals with only one of these disorders. Ketamine given as repeated infusions has been shown to be effective in rapidly reducing PTSD and MDD symptoms in treatment resistant PTSD+MDD individuals. However, knowledge about the mechanisms underlying comorbid PTSD and MDD remain limited. The purpose of this study is to use repeated ketamine infusions as a probe to validate a model of PTSD+MDD that focuses on neuroanatomy and executive functioning.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Ketamine

Six infusions of intravenous 0.5 mg/kg ketamine hydrochloride solution over 3 weeks.

Normal Saline

Six infusions of intravenous normal saline solution over 3 weeks.

Additional Information

Official Study Title

Characterization of Comorbid Post-traumatic Stress Disorder and Major Depressive Disorder Utilizing Ketamine as an Experimental Medicine Probe

Clinical Trial ID

NCT04032301

ParticipAid ID

bkRkNa